This paper found that nicotinamide mononucleotide (NMN), a precursor of nicotinamide adenine dinucleotide (NAD+), can improve insulin sensitivity in muscle in overweight or obese postmenopausal women with prediabetes. The study was conducted in a double-blind, placebo-controlled trial with 80 participants. The participants were randomly assigned to receive either 500 mg of NMN or a placebo twice daily for 12 weeks.
These results suggest that NMN supplementation may be a potential therapeutic option for improving insulin sensitivity in prediabetes. However, further research is needed to confirm these findings and to determine the optimal dose and duration of NMN supplementation.
Read More HERE